Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody

Diane Milenic, Kayhan Garmestani, Ekaterina Dadachova, Lara Chappell, Paul Albert, Donald Hill, Jeffrey Schlom, Martin Brechbiel

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


The data presented within this paper is the first report of a humanized domain-deleted monoclonal antibody (HuCC49ΔCH2) to be utilized in a radioimmunotherapeutic (RIT) application with 213Bi. An initial study indicated that 111In-HuCC49ΔCH2 targets the subcutaneously implanted human colon carcinoma xenograft, LS-174T, when injected via a peritoneal route. The HuCC49ΔCH2 was then radiolabeled with 213Bi, an α-emitting radionuclide with a half-life of 45. 6 minutes, and evaluated for therapeutic efficacy. Dose titration studies indicated that a single dose of 500-1000 μCi, when injected by an intraperitoneal route, resulted in the growth inhibition or regression of the tumor xenograft. The radioimmunotherapeutic effect was found to be dose-dependent. Specificity of the therapeutic efficacy was confirmed in a subsequent experiment with athymic mice bearing TAG-72 negative MIP (human colorectal) xenografts. A preliminary study was also performed to assess a multiple-dose administration of 213Bi-HuCC49ΔCH2. Doses (500 μCi) were administered at 14-day intervals after tumor implantation. A reduction in volume and/or delay in tumor growth was evident following the second and third injections of 213Bi-HuCC49ΔCH2. As further validation of the use of 213Bi-HUCC49ΔCH2 for RIT, a study using 131I was conducted. The overall survival of mice receiving 213Bi-HuCC49ΔCH2 was greater than those that received 131I-HUCC49ΔCH2.

Original languageEnglish (US)
Pages (from-to)135-147
Number of pages13
JournalCancer Biotherapy and Radiopharmaceuticals
Issue number2
StatePublished - 2004
Externally publishedYes


  • Bi
  • Bismuth
  • HuCC49ΔCH2
  • Radioimmunotherapy
  • α-particle

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody'. Together they form a unique fingerprint.

Cite this